Endpoints | Characteristic | HR | 95% CI |
---|---|---|---|
LRFS | |||
 | Age (≤ 50 vs. >  50) | 1.53 | 0.73–3.24 |
 | Sex (male vs. female) | 1.24 | 0.55–2.82 |
 | T stage (T3 vs. T4) | 2.23 | 1.01–4.92 |
 | N stage (N0–1 vs. N2–3) | 1.36 | 0.58–3.19 |
 | Overall stage (III vs. IVA-B) | 2.45 | 1.15–5.22 |
 | RTI (≤ 5 vs. > 5 days) | 6.14 | 2.84–13.22 |
 | Schedule (68 Gy/30 F vs. 70 Gy/33 F) | 1.99 | 0.90–4.40 |
OS | |||
 | Age (≤ 50 vs. >  50) | 2.03 | 1.22–3.38 |
 | Sex (male vs. female) | 0.56 | 0.28–1.09 |
 | T stage (T3 vs. T4) | 2.09 | 1.23–3.54 |
 | N stage (N0–1 vs. N2–3) | 2.42 | 1.46–4.02 |
 | Overall stage (III vs. IVA-B) | 2.72 | 1.65–4.46 |
 | RTI (≤ 5 vs. > 5 days) | 1.48 | 0.87–2.50 |
 | Schedule (68 Gy/30 F vs. 70 Gy/33 F) | 1.29 | 0.72–2.31 |